Search clinical trials for: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg

Total 59 results

Beijing VDJBio Co., LTD.

Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Health Volunteer

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Jiangsu Gensciences lnc.

Not yet recruiting

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Hengenix Biotech Inc

Completed

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

COVID 19

United States
Chengdu Kanghong Biotech Co., Ltd.
University of Wisconsin, Madison

Completed

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)

Neovascular Age-related Macular Degeneration

China
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Sichuan Clover Biopharmaceuticals, Inc.

Recruiting

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Chemotherapy-induced Thrombocytopenia (CIT)

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Recruiting

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Latent Tuberculosis Infection

China
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Type2 Diabetes Mellitus

China
Alexion

Withdrawn

Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

Hypophosphatasia
Tianjin SinoBiotech Ltd.

Completed

Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection

Healthy Subjects

China
Huabo Biopharm Co., Ltd.

Completed

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Beijing Hospital
Changhai Hospital; Xiangya Hospital of Central South University; Peking University... and other collaborators

Not yet recruiting

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Connective Tissue Diseases | Thrombocytopenia

China
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Alexion Pharmaceuticals

Completed

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Type 2 Diabetes Mellitus

China
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
Bio-Thera Solutions
Zhejiang Tumor Hospital

Recruiting

To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
University of Athens

Completed

Anakinra in Hidradenitis Suppurativa

Hidradenitis Suppurativa

Greece
Luye Pharma Group Ltd.
Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)

Not yet recruiting

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

Age Related Macular Degeneration
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

Melanoma Stage IV
Tianjin Medical University Cancer Institute and...

Completed

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

Soft Tissue Sarcoma, Adult, Stage IIB

China
Shandong Simcere-Medgenn Bio-pharmaceutical Co....

Completed

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
EVIVE Biotechnology
Fudan University

Completed

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Peng Yuan

Unknown

Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
Beijing Dongfang Biotech Co., Ltd.

Active, not recruiting

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

Diabetes Mellitus, Type 2 | Overweight

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Novartis Pharmaceuticals

Recruiting

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

FLT3-mutated Acute Myeloid Leukemia

Korea, Republic of, Germany, Italy, Turkey, Czechia, Jordan, Slovenia, Austria, Poland, Japan, Russian Federation, United States, Greece
National Cancer Institute (NCI)

Completed

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Anti-p53 TCR-Gene

United States
Centre for Human Drug Research, Netherlands
Maruho Co., Ltd.

Completed

Intradermal LPS and Antibiotics

Inflammation; Skin

Netherlands
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States
Thomas Jefferson University

Recruiting

Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States, Canada
National Cancer Institute (NCI)

Completed

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Adult Acute Myeloid... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer... and other conditions

United States

Search clinical trials for: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations